

GUIDED THERAPEUTICS INC  
Form 424B3  
November 15, 2012

Filed pursuant to Rule 424(b)(3)  
Registration No. 333-169755

**PROSPECTUS SUPPLEMENT NO. 7**

**28,392,337 Shares of Common Stock**

of

**Guided Therapeutics, Inc.**

---

This prospectus supplement no. 7 supplements and amends the prospectus dated April 10, 2012, previously supplemented on April 19, 2012, May 15, 2012, May 29, 2012, June 20, 2012, July 9, 2012, and August 20, 2012, which constitutes part of our registration statement on Form S-1 (No. 333-169755) relating to up to 28,392,337 shares of our common stock that may be offered for sale by the stockholders named in the prospectus. This prospectus supplement includes our attached quarterly report on Form 10-Q, which was filed with the Securities and Exchange Commission on November 13, 2012.

This prospectus supplement should be read in conjunction with the prospectus, which is to be delivered with this prospectus supplement. This prospectus supplement is qualified by reference to the prospectus, except to the extent that the information in this prospectus supplement updates and supersedes the information contained in the prospectus.

This prospectus supplement is not complete without, and may not be delivered or utilized except in connection with, the prospectus.

**Investing in our common stock involves a high degree of risk. We urge you to carefully read the “Risk Factors” section beginning on page 3 of the prospectus.**

**Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.**

The date of this prospectus supplement is November 15, 2012.

**UNITED STATES SECURITIES AND  
EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 10-Q**

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT  
1934

For the quarterly period ended September 30, 2012

*Commission File No. 0-22179*

**GUIDED THERAPEUTICS, INC.**

(Exact Name of Registrant as Specified in Its Charter)

Delaware

58-2029543

(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)

5835 Peachtree Corners East, Suite D

Norcross, Georgia 30092

Edgar Filing: GUIDED THERAPEUTICS INC - Form 424B3

(Address of principal executive offices) (Zip Code)

(770) 242-8723

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days: Yes [ ] No [X]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-12 of the Exchange Act (Check one):

Large Accelerated filer \_\_\_\_\_ Accelerated filer \_\_\_\_\_ Non-accelerated filer \_\_\_\_\_ Smaller Reporting Company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.

Yes [ ] No [X]

As of November 9, 2012, the registrant had outstanding 62,187,321 shares of Common Stock.

GUIDED THERAPEUTICS, INC. AND SUBSIDIARY

INDEX

Part I. Financial Information	3
Item 1. Financial Statements	3
Condensed Consolidated Balance Sheets (Unaudited) - September 30, 2012 and December 31, 2011	3
Condensed Consolidated Statements of Operations (Unaudited) Three and Nine months ended September 30, 2012 and 2011	4
Condensed Consolidated Statements of Cash Flows (Unaudited) Nine months ended September 30, 2012 and 2011	5
Notes to Condensed Financial Statements (Unaudited)	6
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations	11
Item 3. Quantitative and Qualitative Disclosures About Market Risk	15
Item 4. Controls and Procedures	15
Part II. Other Information	17
Item 1A. Risk Factors	17
Item 6. Exhibits	17
Signatures	18

**PART I - FINANCIAL INFORMATION****ITEM 1. FINANCIAL STATEMENTS**

GUIDED THERAPEUTICS, INC. AND SUBSIDIARY  
 CONDENSED CONSOLIDATED BALANCE SHEETS  
 (Unaudited, in Thousands)

	AS OF	
	September 30, 2012	December 31, 2011
<b>ASSETS</b>		
<b>CURRENT ASSETS:</b>		
Cash and cash equivalents	\$2,609	\$2,200
Accounts receivable, net of allowance for doubtful accounts of \$7 and \$20 at September 30, 2012 and December 31, 2011	65	117
Inventory, net of reserves of \$64 at September 30, 2012 and December 31, 2011	461	520
Other current assets	119	54
Total current assets	3,254	2,891
Property and equipment, net	1,270	1,033
Other assets	247	386
Total noncurrent assets	1,517	1,419
<b>TOTAL ASSETS</b>	<b>\$4,771</b>	<b>\$4,310</b>
<b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>		
<b>CURRENT LIABILITIES:</b>		
Short-term notes payable	\$—	\$30
Current portion of long-term debt	11	25
Notes payable – past due	406	362
Accounts payable	1,040	1,102
Accrued liabilities	608	757
Deferred revenue	582	453
Total current liabilities	2,647	2,729
Long-term debt payable, less current portion	—	4
Total long-term liabilities	—	4
<b>TOTAL LIABILITIES</b>	<b>2,647</b>	<b>2,733</b>
<b>COMMITMENTS &amp; CONTINGENCIES (Note 4)</b>		
<b>STOCKHOLDERS' EQUITY:</b>		
Common stock, \$.001 par value; 145,000 and 100,000 shares authorized, 62,187 and 52,211 shares issued and outstanding, as of September 30, 2012 and December 31, 2011, respectively	62	52
Additional paid-in capital	92,973	86,614
Treasury stock, at cost	(104 )	(104 )
Accumulated deficit	(90,911)	(85,089)
<b>TOTAL GUIDED THERAPEUTICS STOCKHOLDERS' EQUITY</b>	<b>2,020</b>	<b>1,473</b>

Non-controlling interest	104	104
TOTAL STOCKHOLDERS' EQUITY	2,124	1,577
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	\$4,771	\$4,310

The accompanying notes are an integral part of these condensed consolidated financial statements.

**GUIDED THERAPEUTICS, INC. AND SUBSIDIARY**  
**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**  
(Unaudited, in Thousands Except Per Share Data)

	FOR THE THREE MONTHS ENDED SEPTEMBER 30,		FOR THE NINE MONTHS ENDED SEPTEMBER 30,	
	2012	2011	2012	2011
<b>REVENUE:</b>				
Contract and grant revenue	\$693	\$1,021	\$2,326	\$2,701
Sales – devices and disposables	43	—	72	—
Cost of goods sold	55	—	130	—
Gross Loss	(12 )	—	(58 )	—
<b>COSTS AND EXPENSES:</b>				
Research and development	787	709	2,397	2,024
Sales and marketing	132	80	271	200
Claim settlement	—	2,285	—	2,285
General and administrative	732	596	2,714	2,066
Total	1,651	3,670	5,382	6,575
Operating loss	(970 )	(2,649 )	(3,114 )	(3,874 )
OTHER INCOME	—	9	—	53
INTEREST EXPENSE	(16 )	(21 )	(52 )	(62 )
LOSS BEFORE INCOME TAXES	(986 )	(2,661 )	(3,166 )	(3,883 )
PROVISION FOR INCOME TAXES	—	—	—	—
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	\$(986 )	\$(2,661 )	\$(3,166 )	\$(3,883 )
BASIC AND DILUTED NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS	\$(0.02 )	\$(0.05 )	\$(0.06 )	\$(0.08 )
WEIGHTED AVERAGE SHARES OUTSTANDING	60,827	48,813	55,810	48,379



The accompanying notes are an integral part of these condensed consolidated financial statements.

GUIDED THERAPEUTICS, INC. AND SUBSIDIARY  
 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS  
 (Unaudited, in Thousands)

	FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2012    2011	
<b>CASH FLOWS FROM OPERATING ACTIVITIES:</b>		
Net loss	\$(3,166)	\$(3,883)
Adjustments to reconcile net loss to net cash used in operating activities:		
Bad debt expense (recovery)	(8 )	—
Depreciation and amortization	258	18
Stock based compensation	493	347
Issuance of warrants in connection with settlement of claim	—	2,285
Changes in operating assets and liabilities:		
Inventory	60	—
Accounts receivable	59	(39 )
Other current assets	(64 )	(10 )
Accounts payable	(62 )	220
Deferred revenue	129	39
Accrued liabilities	44	(156 )
Other assets	139	(585 )
Total adjustments	1,048	2,119
Net cash used in operating activities	(2,118)	(1,764)
<b>CASH FLOWS FROM INVESTING ACTIVITIES:</b>		
Additions to capitalized software costs	—	(184 )
Additions to fixed assets	(496 )	(264 )
Net cash used in investing activities	(496 )	(448 )
<b>CASH FLOWS FROM FINANCING ACTIVITIES:</b>		
Proceeds from options and warrants exercised	3,072	245
Payments on notes and loan payables	(50 )	(173 )
Net cash provided by financing activities	3,022	72
NET CHANGE IN CASH AND CASH EQUIVALENTS	409	(2,141)
CASH AND CASH EQUIVALENTS, beginning of year	2,200	3,268
CASH AND CASH EQUIVALENTS, end of period	\$2,609	\$1,128
<b>SUPPLEMENTAL SCHEDULE OF:</b>		
Cash paid for interest	\$12	\$2
<b>NONCASH INVESTING AND FINANCING ACTIVITIES:</b>		
Conversion of notes payable into common stock	\$—	\$27

Edgar Filing: GUIDED THERAPEUTICS INC - Form 424B3

Deemed dividends in the form of warrants to purchase common stock	\$2,654	\$—
Conversion of interest to principal	\$—	\$25
Conversion of deferred compensation into common stock	\$148	\$—

The accompanying notes are an integral part of these condensed consolidated financial statements.

5

## **GUIDED THERAPEUTICS, INC. AND SUBSIDIARY**

### **NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

#### **1. BASIS OF PRESENTATION**

The accompanying unaudited condensed consolidated financial statements included herein have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) for interim financial reporting and with the instructions to Form 10-Q and Article 10 of Regulation S-X by Guided Therapeutics, Inc. (formerly SpectRx, Inc.), together with its majority owned subsidiary, InterScan, Inc. (“InterScan”) (formerly Guided Therapeutics, Inc.), collectively referred to herein as the “Company.” Accordingly, they do not include all information and footnotes required by GAAP for complete financial statements. These statements reflect adjustments, all of which are of a normal, recurring nature, and which are, in the opinion of management, necessary to present fairly the Company’s financial position as of September 30, 2012, results of operations for the three and nine months ended September 30, 2012 and 2011, and cash flows for the nine months ended September 30, 2012 and 2011. The results of operations for the three and nine months ended September 30, 2012 are not necessarily indicative of the results for a full fiscal year. Preparing financial statements requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and disclosure of contingent assets and liabilities. Actual results could differ from those estimates. These financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2011.

The Company's prospects must be considered in light of the substantial risks, expenses and difficulties encountered by entrants into the medical device industry. This industry is characterized by an increasing number of participants, intense competition and a high failure rate. The Company has experienced net losses since its inception and, as of September 30, 2012, it had an accumulated deficit of approximately \$90.9 million. Through September 30, 2012, the Company has devoted substantial resources to research and development efforts. The Company does not have significant experience in manufacturing, marketing or selling its products. The Company's development efforts may not result in commercially viable products and it may not be successful in introducing its products. Moreover, required regulatory clearances or approvals may not be obtained. The Company's products may not ever gain market acceptance and the Company may not ever achieve levels of revenue to sustain further development costs and support ongoing operations or achieve profitability. The development and commercialization of the Company's products will require substantial development, regulatory, sales and marketing, manufacturing and other expenditures. The Company expects operating losses to continue through the foreseeable future as it continues to expend substantial resources to complete development of its products, obtain regulatory clearances or approvals and conduct further research and development.

#### **Going Concern**

The Company's financial statements have been prepared and presented on a basis assuming it will continue as a going concern. The factors below raise substantial doubt about the Company's ability to continue as a going concern. The consolidated financial statements do not include any adjustments to reflect the possible future effect on the recoverability and classification of assets or the amounts and classifications of liabilities that may result should the Company be unable to continue as a going concern. Notwithstanding the foregoing, the Company believes it has made progress in stabilizing its financial situation by execution of multiyear contracts with Konica Minolta Opto, Inc., a subsidiary of Konica Minolta, Inc., a Japanese corporation based in Tokyo ("Konica Minolta") and grants from the National Cancer Institute ("NCI"), while at the same time simplifying its capital structure and significantly reducing debt.

At September 30, 2012, the Company had working capital of approximately \$607,000 and it had stockholders' equity of approximately \$2.0 million, primarily due to the recurring losses, offset in part by the recognition of the warrants exchanged as part of the Warrant Exchange Program. As of September 30, 2012, the Company was past due on payments due under its notes payable in the amount of approximately \$406,000.

The Company's capital-raising efforts are ongoing. If sufficient capital cannot be raised during the first quarter of 2013, the Company has plans to curtail operations by reducing discretionary spending and staffing levels, and attempting to operate by only pursuing activities for which it has external financial support, such as under its development agreement with Konica Minolta and additional NCI or other grant funding. However, there can be no assurance that such external financial support will be sufficient to maintain even limited operations or that the Company will be able to raise additional funds on acceptable terms, or at all. In such a case, the Company might be required to enter into unfavorable agreements or, if that is not possible, be unable to continue operations, and to the extent practicable, liquidate and/or file for bankruptcy protection.

The Company could receive additional funding from Konica Minolta or other strategic partners as well as new federal grants that could bring in an additional \$2.7 million. As of September 30, 2012, the Company had warrants exercisable for approximately 20.8 million shares of its common stock outstanding, a substantial majority of which have an exercise price of \$0.65 and \$0.80 per share. Through September 30, 2012, exercises of warrants have generated approximately \$3.0 million and would generate a total of approximately \$14.2 million in cash, assuming full exercise. Management may obtain additional funds through the private sale of preferred stock or debt securities, public and private sales of common stock, funding from collaborative arrangements, and grants, if available, and believes that such financing will be sufficient to support planned operations through the first quarter of 2013.

Assuming the Company receives Food and Drug Administration (“FDA”) approval for its LuViva cervical cancer detection device in early 2013, the Company currently anticipates a late 2013 product launch in the United States. Product launch outside the United States commenced, as expected, in the second half of 2012, but the Company cannot be assured it will be able to continue its product launch on these timetables, or at all.

## **2. SIGNIFICANT ACCOUNTING POLICIES**

The Company’s significant accounting policies were set forth in the audited financial statements and notes thereto for the year ended December 31, 2011 included in its annual report on Form 10-K, filed with the Securities and Exchange Commission (“SEC”).

### **Accounting Standards Updates**

Newly effective accounting standards updates and those not effective until after September 30, 2012, are not expected to have a significant effect on the Company’s financial position or results of operations.

### **Cash and Cash Equivalents**

The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be a cash equivalent.

### Concentration of Credit Risk

The Company, from time to time during the periods covered by these consolidated financial statements, may have bank balances in excess of their insured limits. Management has deemed this as a normal business risk.

### Property and Equipment

Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over estimated useful lives of three to seven years. Leasehold improvements are depreciated at the shorter of the useful life of the asset or the remaining lease term. Depreciation expense is included in general and administrative expense on the statement of operations. Expenditures for repairs and maintenance are expensed as incurred.

### Inventory Valuation

All inventories are stated at lower of cost or market, with cost determined substantially on a “first-in, first-out” basis. Selling, general, and administrative expenses are not inventoried, but are charged to expense when purchased. At September 30, 2012 and December 31, 2011, our inventories were as follows:

	September 30, 2012	December 31, 2011
Raw materials	\$475,662	\$433,007
Work in process	47,760	149,069
Finished goods	1,750	1,960
Inventory reserve	(64,036 )	(64,036 )
Total	\$461,136	\$520,000

## **Significant Customers**

The majority of the Company's revenues were from the Konica Minolta contracts and the NCI grant. Revenue from these sources totaled approximately \$2.3 million or 98% and approximately \$2.7 million or 99% of total revenue for the nine months ended September 30, 2012 and 2011, respectively. Revenue from these sources totaled approximately \$693,000 or 98% and approximately \$1.0 million or 99% of total revenue for the three months ended September 30, 2012 and 2011, respectively. Receivables from these customers accounted for 51% and 48% of total receivables at September 30, 2012 and December 31, 2011, respectively.

## **Accounts Receivable**

The Company performs periodic credit evaluations of its customers' financial condition and generally does not require collateral. The Company reviews all outstanding accounts receivable for collectability on a quarterly basis. An allowance for doubtful accounts is recorded for any amounts deemed uncollectable.

## **Revenue Recognition**

The Company recognizes revenue from contracts on a straight line basis, over the terms of the contract. We recognize revenue from grants based on the grant agreement, at the time the expenses are incurred. Revenue from the sale of the Company's products is recognized upon shipment of such products to its customers.

## **Deferred Revenue**

The Company defers payments received as revenue until earned based on the related contracts on a straight line basis, over the terms of the contract.

## **Valuation of Deferred Taxes**

We account for income taxes in accordance with the liability method. Under the liability method, we recognize deferred assets and liabilities based upon anticipated future tax consequences attributable to differences between financial statement carrying amounts of assets and liabilities and their respective tax bases. We establish a valuation allowance to the extent that it is more likely than not that deferred tax assets will not be utilized against future taxable income. As of December 31, 2011, the Company has approximately \$56.2 million of Net Operating Loss (NOL) carry forward. There is no provision for income taxes at September 30, 2012, due to the NOL. A full valuation allowance



has been recorded related to any deferred tax assets created from the NOL.

### **Stock Option Plan**

The Company measures the cost of employees services received in exchange for equity awards, including stock options, based on the grant date fair value of the awards. The cost will be recognized as compensation expense over the vesting period of the awards.

### **Warrants**

The Company has issued warrants, which allow the warrant holder to purchase one share of stock at a specified price for a specified period of time. The Company records equity instruments, including warrants issued to non-employees, based on the fair value at the date of issue. The fair value of the warrants at date of issuance is estimated using the Black-Scholes Model.

## **3. STOCK-BASED COMPENSATION**

For the three and nine months ended September 30, 2012, stock-based compensation for options attributable to employees, officers and directors was approximately \$143,000 and \$493,000, respectively, and has been included in the Company's third quarter 2012 statement of operations. For the three and nine months ended September 30, 2011, stock-based compensation for options attributable to employees, officers and directors was approximately \$96,000 and \$347,000, respectively, and has been included in the Company's third quarter 2011 statement of operations. Compensation costs for stock options, which vest over time, are recognized over the vesting period. As of September 30, 2012, the Company had approximately \$1.6 million of unrecognized compensation expense related to granted stock options, to be recognized over the remaining vesting period of approximately three years.

#### **4. LITIGATION AND CLAIMS**

From time to time, the Company may be involved in various legal proceedings and claims arising in the ordinary course of business. Management believes that the disposition of these matters, individually or in the aggregate, is not expected to have a material adverse effect on the Company's financial condition. However, depending on the amount and timing of such disposition, an unfavorable resolution of some or all of these matters could materially affect the future results of operations or cash flows in a particular period.

As of September 30, 2012 and December 31, 2011, there was no accrual recorded for any potential losses related to pending litigation.

#### **5. STOCKHOLDERS' EQUITY**

##### **Common Stock**

The Company has authorized 145 million shares of common stock with \$0.001 par value, 62,187,321 of which were outstanding as of September 30, 2012. For the quarter ended September 30, 2012, we issued 6,297,258 shares, in connection with the exercise of outstanding warrants.

##### **Preferred Stock**

The Company has authorized 5,000,000 shares of preferred stock with a \$.001 par value. The board of directors has the authority to issue these shares and to set dividends, voting and conversion rights, redemption provisions, liquidation preferences, and other rights and restrictions. The board of directors designated 525,000 shares of the preferred stock as redeemable convertible preferred stock. None of the Company's preferred stock was outstanding at September 30, 2012.

##### **Stock Options**

Edgar Filing: GUIDED THERAPEUTICS INC - Form 424B3

The Company has a 1995 stock option plan (the “Plan”) approved by its stockholders for officers, directors and key employees of the Company and consultants to the Company. Participants are eligible to receive incentive and/or nonqualified stock options. The aggregate number of shares that may be granted under the Plan is 13,255,219 shares. The Plan is administered by the compensation committee of the board of directors. The selection of participants, grant of options, determination of price and other conditions relating to the exercise of options are determined by the compensation committee of the board of directors and administered in accordance with the Plan.

Both incentive stock options and non-qualified options granted to employees, officers and directors under the Plan are exercisable for a period of up to 10 years from the date of grant, at an exercise price that is not less than the fair market value of the common stock on the date of the grant. The options typically vest in installments of 1/48 of the options outstanding every month.

A summary of the Company’s activity under the Plan, as of September 30, 2012, and changes during the nine months then ended is as follows:

	Shares	Weighted average exercise price
Outstanding, January 1, 2012	6,862,167	\$ 0.70
Granted	82,500	\$ 0.80
Exercised	(231,461 )	\$ 0.27
Expired	(144,000 )	\$ 2.87
Outstanding, September 30, 2012	6,569,206	\$ 0.67
Vested and exercisable, September 30, 2012	4,921,215	\$ 0.48

The Company estimates the fair value of stock options using a Black-Scholes valuation model. Key input assumptions used to estimate the fair value of stock options include the expected term, expected volatility of the Company’s stock, the risk free interest rate, option forfeiture rates, and dividends, if any. The expected term of the options is based upon the historical term until exercise or expiration of all granted options. The expected volatility is derived from the historical volatility of the Company’s stock on the OTCBB market for a period that matches the expected term of the option. The risk-free interest rate is the constant maturity rate published by the U.S. Federal Reserve Board that corresponds to the expected term of the option.

Under the Plan, a total of 6,686,013 shares remained available at September 30, 2012, and 6,569,206 shares were outstanding as of that date, bringing the total number of shares subject to stock options outstanding and those remaining available for issue to 13,255,219 shares of common stock as of September 30, 2012. The Plan allows the issuance of incentive stock options, nonqualified stock options, and stock purchase rights. The exercise price of options is determined by the Company's board of directors, but incentive stock options must be granted at an exercise price equal to the fair market value of the Company's common stock as of the grant date. Options historically granted have generally become exercisable over four years and expire ten years from the date of grant.

In January 2002, the Company assumed the Sterling Medivations 2000 Stock Option Plan, which authorizes the issuance of up to 93,765 shares of the Company's common stock. No options have been issued under this plan.

## Warrants

In July 2012, the Company completed a warrant exchange program, pursuant to which it exchanged warrants exercisable for a total of 15,941,640 shares of common stock, or 56.29% of the warrants eligible to participate, for three classes of new warrants. These exchanges resulted in a deemed dividend of approximately \$2.65 million, reflected as a non-cash disclosure in this quarterly financial statement of cash flows. The first class of new warrants expired on September 17, 2012 and carried an exercise price of \$0.40, \$0.45 or \$0.50, depending on the date exercised. The second class of new warrants carries a one-year extension from the original expiration date and is exercisable at \$0.65. The third class of new warrants carries a two-year extension from the original expiration date and is exercisable at \$0.80. As of September 30, 2012, the Company had issued 7,042,689 shares of common stock and received approximately \$2.9 million in cash, in connection with the exercise of the first class of new warrants (the remainder of which, previously exercisable for 774,192 shares of common stock, expired pursuant to their terms).

The following table summarizes transactions involving the Company's outstanding warrants to purchase common stock for the nine months ended September 30, 2012:

	Warrants (Underlying Shares)
Outstanding, January 1, 2012	31,217,117
Issuances	—
Canceled / Expired	(844,966 )
Exercised	(9,570,639 )
Outstanding, September 30, 2012	20,801,512

The Company had the following shares reserved for the warrants outstanding as of September 30, 2012:

Warrants (Underlying Shares)	Exercise Price	Expiration Date
12,384,777	(1) \$0.65	03/01/2013
471,856	(2) \$0.65	07/26/2013
3,590,525	(3) \$0.65	03/01/2014
471,856	(4) \$0.80	07/26/2014
3,590,522	(5) \$0.80	03/01/2015
6,790	(6) \$1.01	09/10/2015
285,186	(7) \$1.05	11/20/2016
20,801,512		

- (1) Consists of outstanding warrants issued in connection with various financings, but amended or originally issued on February 26, 2010 to expire on March 1, 2013.
- (2) Consists of outstanding warrants issued in connection with the warrant exchange program in June 2012, to expire on July 26, 2013.
- (3) Consists of outstanding warrants issued in connection with the warrant exchange program in June 2012, to expire on March 1, 2014.
- (4) Consists of outstanding warrants issued in connection with the warrant exchange program in June 2012, to expire on July 26, 2014.
- (5) Consists of outstanding warrants issued in connection with the warrant exchange program in June 2012, to expire on March 1, 2015.
- (6) Consists of outstanding warrants issued in conjunction with a private placement on September 10, 2010, to expire on September 10, 2015.
- (7) Consists of outstanding warrants issued in conjunction with a private placement on November 21, 2011, to expire on November 20, 2016.

## **6. LOSS PER COMMON SHARE**

Basic net loss per share attributable to common stockholders amounts are computed by dividing the net loss plus preferred stock dividends and deemed dividends on preferred stock by the weighted average number of common shares outstanding during the period.

## **7. NOTES PAYABLE**

### **Loan Payable**

At December 31, 2009, the Company maintained a line of credit in the amount of \$75,000 with Pacific International Bank of Seattle, Washington. This line was converted to a 36 months straight-line amortizing loan on February 24, 2010, with monthly principal and interest payment of \$2,220 per month, due February 2013. Interest is charged at a rate of 7.5%. At September 30, 2012, a balance of approximately \$11,000 was outstanding, which is classified as current loan payable. For the same period in 2011, the balance was approximately \$36,000.

### **Notes Payable – Past Due**

At September 30, 2012 the Company was past due on two short-term notes for approximately \$406,000 of principal and accrued interest. For the same period in 2011, the balance was approximately \$353,000. These notes were due on demand and interest is charged at rates ranging between 15-18%.

## **ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

Statements in this report which express "belief," "anticipation" or "expectation," as well as other statements which are not historical facts, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from historical results or anticipated results, including those set forth under "Risk Factors" below and elsewhere in this report, as well as in our annual report on Form 10-K for the year ended December 31, 2011. Examples of these uncertainties and risks include, but are not limited to:

- the dependence on potential strategic partners or outside investors for funding, development assistance, clinical trials, distribution and marketing of some of our products;
- access to sufficient debt or equity capital to meet our operating and financial needs;
- the effectiveness and ultimate market acceptance of our products;
  
- whether our products in development will prove safe, feasible and effective;
- whether and when we or any potential strategic partners will obtain approval from the U.S FDA and corresponding foreign agencies;
  
- our need to achieve manufacturing scale-up in a timely manner, and our need to provide for the efficient manufacturing of sufficient quantities of our products;
- the lack of immediate alternate sources of supply for some critical components of our products;
  
- our patent and intellectual property position; and
- the need to fully develop the marketing, distribution, customer service and technical support and other functions critical to the success of our product lines.

The following discussion should be read in conjunction with our financial statements and notes thereto included elsewhere in this report.

## **OVERVIEW**

We are a medical technology company focused on developing innovative medical devices that have the potential to improve healthcare. Our primary focus is the development of our LuViva non-invasive cervical cancer detection device and extension of our cancer detection technology into other cancers, especially lung and esophageal. Our technology, including products in research and development, primarily relates to biophotonics technology for the non-invasive detection of cancers, including cervical cancer.

We are a Delaware corporation, originally incorporated in 1992 under the name “SpectRx, Inc.,” and, on February 22, 2008, changed our name to Guided Therapeutics, Inc. At the same time, we renamed our majority owned subsidiary, InterScan, which originally had been incorporated as “Guided Therapeutics.”

Since our inception, we have raised capital through the private sale of preferred stock and debt securities, public and private sales of common stock, funding from collaborative arrangements, and grants.

Our prospects must be considered in light of the substantial risks, expenses and difficulties encountered by entrants into the medical device industry. This industry is characterized by an increasing number of participants, intense competition and a high failure rate. We have experienced operating losses since our inception and, as of September 30, 2012, we had an accumulated deficit of about \$90.9 million. To date, we have engaged primarily in research and development efforts. We do not have significant experience in manufacturing, marketing or selling our products. Our development efforts may not result in commercially viable products and we may not be successful in introducing our products. Moreover, required regulatory clearances or approvals may not be obtained in a timely manner, or at all. Our products may not ever gain market acceptance and we may not ever generate significant revenues or achieve profitability. The development and commercialization of our products requires substantial development, regulatory, sales and marketing, manufacturing and other expenditures. We expect our operating losses to continue through at least the end of 2012 as we continue to expend substantial resources to introduce LuViva, further the development of our other products, obtain regulatory clearances or approvals, build our marketing, sales, manufacturing and finance organizations and conduct further research and development.

Our product revenues to date have been limited. In 2011 and 2010, the majority of our revenues were from private sales of our common stock, grants from the NCI and our collaborative arrangements with Konica Minolta. We expect that the majority of our revenue in 2012 will be derived from similar sources, as well as cash received upon exercise of outstanding warrants.

## **CRITICAL ACCOUNTING POLICIES**

Our material accounting policies, which we believe are the most critical to an investors understanding of our financial results and condition, are discussed below. Because we are still early in our enterprise development, the number of these policies requiring explanation is limited. As we begin to generate increased revenue from different sources, we expect that the number of applicable policies and complexity of the judgments required will increase.



Currently, our policies that could require critical management judgment are in the areas of revenue recognition, reserves for accounts receivable and inventory valuation.

**Revenue Recognition:** We recognize revenue from contracts on a straight line basis, over the terms of the contract. We recognize revenue from grants based on the grant agreement, at the time the expenses are incurred. Revenue from the sale of the Company's products is recognized upon shipment of such products to its customers.

**Valuation of Deferred Taxes:** We account for income taxes in accordance with the liability method. Under the liability method, we recognize deferred assets and liabilities based upon anticipated future tax consequences attributable to differences between financial statement carrying amounts of assets and liabilities and their respective tax bases. We establish a valuation allowance to the extent that it is more likely than not that deferred tax assets will not be utilized against future taxable income.

**Stock Option Plan:** We measure the cost of employees services received in exchange for equity awards, including stock options, based on the grant date fair value of the awards. The cost will be recognized as compensation expense over the vesting period of the awards.

**Warrants:** We have issued warrants, which allow the warrant holder to purchase one share of stock at a specified price for a specified period of time. We record equity instruments, including warrants issued to non-employees, based on the fair value at the date of issue. The fair value of the warrants, at date of issuance, is estimated using the Black-Scholes Model.

**Allowance for Inventory Valuation:** We estimate losses from obsolete and damaged inventories quarterly and revise our reserves as a result.

**Allowance for Accounts Receivable:** We estimate losses from the inability of our customers to make required payments and periodically review the payment history of each of our customers, as well as their financial condition, and revise our reserves as a result.

## RESULTS OF OPERATIONS

### COMPARISON OF THE THREE MONTHS ENDED SEPTEMBER 30, 2012 AND 2011

**Revenue:** Net revenue decreased to approximately \$693,000 for the three months ended September 30, 2012 from approximately \$1.0 million for the same period in 2011. Net revenue was lower for the three months ended September 30, 2012 than the comparable period in 2011, due to the decrease in revenue from contracts relating to our cervical cancer detection technology and the Konica Minolta co-development agreement.

**Sales Revenue, Cost of Sales and Gross Loss from Devices:** Revenue from the sale of a demonstration LuViva device, for the quarter ended September 30, 2012, was approximately \$43,000, with related cost of sales of approximately \$55,000; resulting in a loss of approximately \$12,000 on the device. We did not have any sales of devices and, therefore, did not incur any cost of sales of devices, in the same period in 2011.

**Research and Development Expenses:** Research and development expenses increased to approximately \$787,000 for the three months ended September 30, 2012, compared to \$709,000 for the same period in 2011. The increase, of approximately \$78,000, was primarily due to an increase in research and development expenses for the cervical cancer detection products.

**Sales and Marketing Expenses:** Sales and marketing expenses were approximately \$132,000 during the three months ended September 30, 2012, compared to \$80,000 for the same period in 2011. The increase, of approximately \$52,000, was primarily due to an increase in expenses relating to international marketing efforts for our cervical cancer detection products in development.

**General and Administrative Expenses:** General and administrative expenses decreased to approximately \$732,000 during the three months ended September 30, 2012, compared to \$2.9 million for the same period in 2011. The decrease of approximately \$2.1 million is primarily related to the issuance of warrants exercisable for 2.6 million shares of common stock in connection with settlement of a claim during the three months ended September 30, 2011.

Other Income: Other income was zero for the three months ended September 30, 2012, compared to \$9,000 for the same period in 2011. Other income for the three months ended September 30, 2011, was associated with a seconded employee from Konica Minolta.

Interest Expense: Interest expense decreased to approximately \$16,000 for the three months ended September 30, 2012, as compared to expense of approximately \$21,000, for the same period in 2011. The decrease in interest expense was a result of lower loan balances for the three months ended September 30, 2012.

Taxes: There is no provision for income taxes, for the three months ended September 30, 2012, due to the approximately \$56.2 NOL carry forward at December 31, 2011. A full valuation allowance has been recorded related to any deferred tax assets created from the NOL.

Net loss was approximately \$986,000 for the three months ended September 30, 2012, compared to a net loss of approximately \$2.7 million for the same period in 2011, for the reasons described above.

#### **COMPARISON OF THE NINE MONTHS ENDED SEPTEMBER 30, 2012 AND 2011**

Revenue: Net revenue decreased to approximately \$2.3 million for the nine months ended September 30, 2012, from approximately \$2.7 million for the same period in 2011. Net revenue was lower for the nine months ended September 30, 2012, than the comparable period in 2011, due to the decrease in revenue from contracts relating to our cervical cancer detection technology and the KMOT co-development agreement.

Sales Revenue, Cost of Sales and Gross Loss from Devices: Revenue from the sale of a demonstration LuViva device, for the nine months ended September 30, 2012, was approximately \$72,000, with related cost of sales of approximately \$130,000; resulting in a loss of approximately \$58,000 on the device. We did not have any sales of devices and, therefore, did not incur any cost of sales of devices in the same period in 2011.

**Research and Development Expenses:** Research and development expenses increased to approximately \$2.4 million for the nine months ended September 30, 2012, compared to approximately \$2.0 million for the same period in 2011. The increase, of approximately \$373,000, is due to an increase in expenses for research and development of the cervical cancer detection products.

**Sales and Marketing Expenses:** Sales and marketing expenses were approximately \$271,000 during the nine months ended September 30, 2012, compared to \$200,000 for the same period in 2011. The increase, of approximately \$71,000, was primarily due to an increase in expenses relating to marketing efforts for the cervical cancer detection products in development.

**General and Administrative Expenses:** General and administrative expenses decreased to approximately \$2.7 million during the nine months ended September 30, 2012, compared to approximately \$4.4 million for the same period in 2011. The decrease of approximately \$1.7 million is primarily related to approximately \$2.1 million in cost related to the issuance of warrants exercisable for 2.6 million shares of common stock in connection with settlement of a claim during the nine months ended September 30, 2011, offset in part by (1) a one-time write-off of obsolete materials, due to improved technology and design of our device of approximately \$270,000, (2) an increase in employee stock option expense of approximately \$127,000, due to employee stock options, and (3) an increase in professional fees, related to our products under development.

**Other Income:** Other income was zero for the nine months ended September 30, 2012, compared to \$53,000 for the same period in 2011. Other income for the nine months ended September 30, 2011, was associated with a seconded employee from Konica Minolta.

**Interest Expense:** Interest expense decreased to approximately \$52,000 for the nine months ended September 30, 2012, as compared to approximately \$62,000 for the same period in 2011. The decrease is primarily due to the decrease in interest expense on lower loan balances for the nine months ended September 30, 2012.

**Taxes:** There is no provision for income taxes, for the nine months ended September 30, 2012, due to the approximately \$56.2 NOL carry forward at December 31, 2011. A full valuation allowance has been recorded related to any deferred tax assets created from the NOL.

Net loss was approximately \$3.2 million during the nine months ended September 30, 2012, compared to approximately \$3.9 million for the same period in 2011, for the reasons described above.

## LIQUIDITY AND CAPITAL RESOURCES

Since our inception, we have raised capital through the private sale of preferred stock and debt securities, public and private sales of common stock, funding from collaborative arrangements and grants. At September 30, 2012, we had cash of approximately \$2.6 million and working capital of approximately \$607,000.

Our major cash flows for the nine months ended September 30, 2012, consisted of cash out-flows of approximately \$2.1 million from operations, including approximately \$3.2 million of net loss, cash outflow of \$496,000 from investing activities and net cash from financing activities of approximately \$3.0 million, which primarily represents the proceeds received from the exercise of outstanding warrants and options, offset in part by cash utilized for loan repayment.

In July 12, 2012, we completed a warrant exchange program, pursuant to which we exchanged warrants exercisable for a total of 15,941,640 shares of common stock, or 56.29% of the warrants eligible to participate, for three classes of new warrants. The first class of new warrants expired on September 17, 2012 and carried an exercise price of \$0.40, \$0.45 or \$0.50, depending on the date exercised. The second class of new warrants carries a one-year extension from the original expiration date and is exercisable at \$0.65. The third class of new warrants carries a two-year extension from the original expiration date and is exercisable at \$0.80. As of September 30, 2012, we had issued 7,042,689 shares of common stock and received approximately \$2.9 million in cash, in connection with the exercise of the first class of new warrants (the remainder of which, previously exercisable for 774,192 shares of common stock, expired pursuant to their terms).

In June 2012, we extended our existing agreement with Konica Minolta for development of our biophotonic platform specific to the detection of esophageal cancer for an additional year, effective May 1, 2012. In this agreement, we are providing Konica Minolta with technical, regulatory and clinical development of our biophotonic platform device for esophageal cancer detection. We received approximately \$1.72 million in 2011 from Konica Minolta under this development agreement and expect to receive a total of \$1.6 million for the third year of development (May 1, 2012 to April 30, 2013). Pursuant to the assigned task agreement, we retain all rights to use of our cervical cancer detection technology as applied to lung and biliary cancer (previously shared with Konica Minolta under the original assigned task agreement). Also in June 2012, we extended our collaboration agreement with Konica Minolta for the development of spectroscopic technology for an additional year, effective April 20, 2012. We have received \$400,000 pursuant to this extension.

On November 21, 2011, we completed a private placement of 2,056,436 shares of common stock at a purchase price of \$0.84 per share, pursuant to which we raised approximately \$1.7 million. For each share of common stock issued, subscribers received warrants exercisable for the purchase of 1/10 of one share of common stock (in the aggregate, 285,186 shares) at an exercise price of \$1.05 per share. The warrants have a five-year term.

We will be required to raise additional funds through public or private financing, additional collaborative relationships or other arrangements in addition to these sources. We believe our existing and available capital resources will be sufficient to satisfy our funding requirements through the first quarter of 2013. We are evaluating various options to further reduce our cash requirements to operate at a reduced rate, as well as options to raise additional funds, including loans using certain assets as collateral.

Substantial capital will be required to develop our products, including completing product testing and clinical trials, obtaining all required U.S. and foreign regulatory approvals and clearances, and commencing and scaling up manufacturing and marketing our products. Any failure to obtain capital would have a material adverse effect on our business, financial condition and results of operations.

Our financial statements have been prepared and presented on a basis assuming we will continue as a going concern. The above factors raise substantial doubt about our ability to continue as a going concern, as more fully discussed in Note 1 to the consolidated financial statements contained herein and in the report of our independent registered public accounting firm accompanying our financial statements contained in our annual report on Form 10-K for the year ended December 31, 2011.

### **Off-Balance Sheet Arrangements**

We have no material off-balance sheet arrangements, no special purpose entities, and no activities that include non-exchange-traded contracts accounted for at fair value.

### **ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

Not applicable.

## **ITEM 4. CONTROLS AND PROCEDURES**

### **Disclosure Controls and Procedures**

The Company under the supervision and with the participation of management, including the Chief Executive Officer (principal executive officer) and the Chief Financial Officer (principal financial officer), evaluated the effectiveness of our “disclosure controls and procedures” (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”)) as of September 30, 2012. The controls and procedures currently used by the Company to calculate and record inventory is not operating effectively. Additionally, the Company lacks the resources to properly research and account for complex transactions. The combination of these controls deficiencies have resulted in a material weakness in our internal control over financial reporting.

Based on that evaluation, the Chief Executive Officer and the Chief Financial Officer concluded that our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) were not effective as of September 30, 2012 to provide reasonable assurance that (1) information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and (2) information required to be disclosed by us in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosures.

The effectiveness of any system of controls and procedures is subject to certain limitations, and, as a result, there can be no assurance that our controls and procedures will detect all errors or fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system will be attained.

### **Changes in Internal Control Over Financial Reporting**

There has been no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended September 30, 2012 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.



## **PART II - OTHER INFORMATION**

### **ITEM 1A. RISK FACTORS**

Please refer to Part I, Item 1A, "Risk Factors," in our annual report on Form 10-K for the year ended December 31, 2011, for information regarding factors that could affect our results of operations, financial condition and liquidity.

### **ITEM 6. EXHIBITS**

#### **EXHIBIT INDEX**

#### **EXHIBITS**

<b>Exhibit Number</b>	<b>Exhibit Description</b>
3.1	Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 of the Company's report on Form 8-K, filed March 23, 2012).
31	Rule 13a-14(a)/15d-14(a) Certification
32	Section 1350 Certification
101	XBRL

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

GUIDED THERAPEUTICS, INC.

/s/ MARK L. FAUPEL

By: Mark L. Faupel  
President, Chief Executive Officer and  
Acting Chief Financial Officer

Date: November 13, 2012

